This invention provides the use of CCI-779 in the treatment of neoplasms. A pharmaceutical composition useful in treating a neoplasm in a mammal in need thereof, which comprises an effective amount of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779)as an active ingredient.